Intrathecal trastuzumab: dose matters

Acta Oncol. 2012 Sep;51(7):955-6. doi: 10.3109/0284186X.2012.673736. Epub 2012 Apr 23.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Aged
  • Antibodies, Monoclonal, Humanized / administration & dosage*
  • Antibodies, Monoclonal, Humanized / blood
  • Antibodies, Monoclonal, Humanized / cerebrospinal fluid
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / blood
  • Antineoplastic Agents / cerebrospinal fluid
  • Biomarkers, Tumor / analysis*
  • Bone Neoplasms / secondary
  • Brain Neoplasms / drug therapy
  • Brain Neoplasms / radiotherapy
  • Brain Neoplasms / secondary
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology*
  • Cranial Irradiation
  • Drug Administration Schedule
  • Female
  • Humans
  • Injections, Spinal*
  • Meningeal Neoplasms / drug therapy*
  • Meningeal Neoplasms / secondary
  • Receptor, ErbB-2 / analysis*
  • Spinal Puncture
  • Trastuzumab
  • Treatment Outcome
  • Up-Regulation

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Biomarkers, Tumor
  • ERBB2 protein, human
  • Receptor, ErbB-2
  • Trastuzumab